Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities[1].
Indimitecan (LMP776) (0-100 μM) shows antiproliferative potencies against various human cancer cell lines, with mean-graph midpoint (MGM) of 0.079 ± 0.023 μM[1].
Indimitecan shows potent DNA cleavage due to Top1 inhibition[1].
Indimitecan can be substrates for metabolic ketone reductases[1].
Cell Proliferation Assay[1]
| Cell Line: | HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, MCF-7 |
| Concentration: | 0-100 μM |
| Incubation Time: | |
| Result: | Showed growth inhibition with GI50s of <0.01, <0.01, 0.04, <0.01, 0.08, <0.01, <0.01 and 0.01 μM against HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145 and MCF-7 cells, respectively. And the mean-graph midpoint (MGM) for growth inhibition of all human cancer cell lines successfully tested (the National Cancer Institute's developmental therapeutics assay (the "NCI60")) was 0.079 ± 0.023 μM. |